

Noninvasive preimplantation genetic test for aneuploidy (NIPGT-A) has a lower false positive rate than that of the invasive PGT-A

L.D. Vagnini², C.G. Petersen^{1,2}, A. Renzi², J.B.A. Oliveira^{1,2}, A.H. Oliani³, R. Nakano⁴, C.G. Almodin⁵, C. Marcondes⁶, A. Ceschin⁷, A. Amaral⁸, E. Borges Jr⁹, A. Castelo Branco¹⁰, J.B. Soares¹¹, J. Lopes¹², J.G. Franco Jr.^{1,2}

¹Paulista Center for Diagnosis Research and Training, Ribeirao Preto, Brazil.
²Centre for Human Reproduction Prof Franco Jr, Ribeirao Preto, Brazil.
³Sao Jose do Rio Preto School of Medicine FAMERP, Sao Jose do Rio Preto, Brazil.
⁴Ferticlin Human Fertility Clinic, Sao Paulo, Brazil.
⁵Materbaby, Maringa, Brazil.
⁶Santista Nucleus of Human Reproduction, Santos, Brazil.
⁷Feliccita Fertility Institute, Curitiba, Brazil.
⁸Genesis Human Reproduction Assistance Center, Brasilia, Brazil.
⁹Fertility Medical Group, Research, Sao Paulo, Brazil.
¹⁰Art Fertil Human Reproduction Clinic, Recife, Brazil.
¹¹Alpha Project - Alliance of Assisted Fertilization Laboratories, Sao Paulo, Brazil.
¹²CENAFERT, Salvador, Brazil.

Study question

Does NIPGT-A have lower false positive rates (FPR) than invasive PGT-A?

Methods

This cohort study included a total of 44 blastocysts vitrified on day 5 that were previously biopsied for invasive PGT-A and presented a diagnosis of aneuploidy. The embryos were donated under informed consent by patients following the Human Medical Authority regulations. Blastocysts were thawed and cultured in 15µl drops of culture medium under oil. After their expansion (4-8hours), the blastocysts were transferred to NGS tubes and their corresponding spent media were collected for analysis. The DNA of all samples (spent culture medium and whole embryo) was amplified by the MALBAC® technology (Yikon Genomics). The samples were subjected to next-generation sequencing (NGS) using Illumina MiSeq® System. The ploidy status results obtained from ChromGo™ software (Yikon Genomics) for culture medium and whole embryo were compared to determine the accuracy of NIPGT-A for screening chromosomal abnormalities in each embryo.

Table 1. NIPGT-A and Invasive PGT-A results

A) NIPGT-A	Whole Embryo	
	Aneuploidy	Normal
Aneuploidy	33	3
Normal	0	8
PPV: 91.7% FPR: 8.3%		

B) Invasive PGT-A	Whole Embryo	
	Aneuploidy	Normal
Aneuploidy	33	11
Normal	----	----
PPV: 75.0% FPR: 25.0%		

Results

DNA from all 44 spent media samples and whole embryos were successfully amplified. Comparing the results of NIPGT-A and whole embryos sequencing, the positive predictive value (PPV) was 91.7% and the FPR was 8.3% (Table 1A). On the other hand, comparing the whole embryo and invasive PGT-A results, the PPV was 75.0%, and the FPR was 25.0% (Table 1B). Both NIPGT-A and invasive PGT-A had a negative predictive value (NPV) of 100% and a false negative rate (FNR) of 0%. In the eleven cases of disagreement the results are presented in the Table 2.

Conclusion

When DNA sequencing from whole embryo cells was used as the gold-standard, the FPR of NIPGT-A was 3-times smaller than that obtained with invasive PGT-A. NIPGT-A has a lower FPR than invasive PGT-A and does not require micro-manipulation skills, avoiding trophoctoderm biopsies trauma and seems to provide more accurate results corresponding to the ploidy status of the whole embryo. Thereby NIPGT-A should be considered as the test of choice for genetic evaluation of the embryo.

Table 2. Disagreement results of whole embryo, NIPGT-A and invasive PGT-A

Whole embryo	NIPGT-A	Invasive PGT-A
46,XY	46,XY	XY,+1q(x3),+3q(x3)
46,XY	46,XY	XY,-2(x1)
46,XY	XY,-1(x1),-9q(x1)	XY,+9q(x3)
46,XX	46,XX	XX,+9q(x3)
46,XX	46,XX	XX,-4(x1)
46,XY	46,XY	X0, multiple abnormalities
46,XX	46,XX	XX,+13(x3)
46,XY	XY,-1(x1),-9(x1),-19(x1),-21(x1)	XY,-9(x1)
46,XX	46,XX	XX,+1q(x3)
46,XY	45,XY,-8(X1)	XY,-8q(x1)
46,XX	46,XX	XX,-3p(x1),-19p(x1)